The antitumour agent doxorubicin (DOX), an anthracycline antibiotic interacts with multiple cellular targets which possibly govern its cytotoxic activity (Riggs, 1992) . Although the clinical efficacy of DOX has been documented in a number of tumour types, the development of resistance with repeated courses of chemotherapy is not uncommon (Riggs, 1992) . This form of resistance which is 'acquired' has been characterised in a variety of model systems selected by prolonged exposure to DOX (Endicott & Ling, 1989) . Since a precise target governing antitumour effects of DOX have not been defined, the mechanisms of resistance have been equally elusive. However, the identification of overexpression of membrane P-glycoprotein (PGP) responsible for cellular efflux of drug and/or alterations in topoisomerase II (TOPO II) in model systems, underscore the significance of these putative targets (Endicott & Ling, 1989; Ganapathi et al., 1989) .
The search for agents to modulate chemosensitivity of tumours is of potential importance. Characteristics of agents which modulate the multidrug resistant (MDR) phenotype have been recently reviewed (Ford & Hait, 1990) . In general, the interaction of the modulating agents with P-glycoprotein resulting in increased drug accumulation has been an accepted mechanism of action (Endicott & Ling, 1989; Ford & Hait, 1990) . While MDR modulating agents invariably increase drug accumulation, a role for such alterations directly contributing to a cytotoxic response are dependent on the type of antitumour agent (Ganapathi et al., 1991b ).
Since we originally reported (Ganapathi & Grabowski, 1983 ) the modulation of DOX cytotoxicity by the calmodulin inhibitor trifluoperazine (TFP), our subsequent studies have demonstrated that the effect of TFP in modulating cytotoxicity of DOX and other inhibitors of topoisomerase II is usually not correlative with the increase in cellular drug levels (Ganapathi et al., 1989; Ganapathi et al., 1991b) . Prolonged vs pulse exposure to DOX plus TFP is also significantly more cytotoxic than DOX alone in both wild-type or resistant tumour cells (Ganapathi et al., 1984) . Since the use of MDR modulating agents in initial treatment regimens to prevent emergence of drug resistance has been suggested (Salmon et al., 1991) , we have pharmacologically and biochemically characterised L1210 mouse leukaemia cells selected for resistance to a combination of DOX plus TFP. Results from this study suggest that while mechanisms of resistance are qualitatively similar to that observed with cells selected for resistance to DOX alone, minimally cytotoxic concentrations of DOX alone in combination with non-cytotoxic levels of TFP can induce the selection of > 30-fold DOX-resistant cells with the MDR phenotype.
Materials and methods
Ascites from a mouse bearing L1210 lymphoid leukaemia was used to establish the in vitro cell line (Ganapathi & Grabowski, 1988 (Ganapathi & Grabowski, 1988 (Ganapathi & Grabowski, 1988 (Ganapathi & Grabowski, 1988) and liquid scintillation respectively (Kamath et al., 1991) . Experiments on drug retention were carried out by preloading cells with the IC50 of DOX ± 5iM TFP for 3 h. Cells were subsequently centrifuged, washed and resuspended in medium in the absence of 5;LM TFP. Samples were retrieved at 15-30 min intervals over 120 min and cellular DOX levels quantified as described earlier (Ganapathi & Grabowski, 1988) . (Kohn et al., 1981) . Details of the method for determining DNA single-strand breaks (DNA-SSB) by DOX and VP-16 have been previously described (Ganapathi et al., 1991a; Kamath et al., 1991) . Elution with tetrapropylammonium hydroxide-EDTA, 0.1% SDS, pH 12.1 was carried out at a flow rate of 0.03-0.04 ml min-' with fractions collected at 3 h intervals over 18 h for DOX treated cells, and a flow rate of 0.12-0.16mlmin-' with fractions collected at 5min intervals over 30min for VP-16 treated cells.
Immunoblotting for previously described (Ganapathi et al., 1989) . Protein content in nuclear extracts was determined by the bicinchoninic acid method (Smith et al., 1985) . Gel electrophoresis by SDS-PAGE was carried out as originally described by Laemmli (1970) . Briefly, protein (50 1fg) from nuclear extracts was run on gels using a 4% stacker and 5% resolving gel. The nitrocellulose following electroblotting (Towbin et al., 1979) of the gel was probed with polyclonal antiserum FHD-29 which simultaneously recognises the 170kDa and 180kDa isoforms of topoisomerase II. The binding of rabbit antisera to TOPO II was detected using goat anti-rabbit alkaline phosphatase conjugated antibody and 5-bromo-4-chloro-3-indolyl phosphate (BCIP)/nitro blue tetrazolium (NBT) as the substrate for colour development.
Detection ofphosphorylated P-glycoprotein Log-phase cultures of L1210/S and L1210/DT cells in phosphate free RPMI 1640 supplemented with 2 mM L-glutamine and 10% foetal bovine serum were labelled for 2-3 h with carrier-free [32P]orthophosphoric acid (0.83 mCi ml-') at 37°C in a 95% air plus 5% CO2 atmosphere (Ganapathi et al., 1991a) . Cells were pelleted, lysed and PGP immunoprecipitated with C-219 monoclonal antibody (Centocor Inc., Malvern, Pennsylvania) as previously described (Anderson & Blobel, 1983; Ganapathi et al., 1991a (Kamath et al., 1991) .
The cellular retention of DOX in L121O/S and L1210/DT cells is outlined in Figure 3 . The experimental strategy of using different concentrations of doxorubicin for the L1210/S vs Li2I1/DT cells for treatment with or without trifluoperazine was carried out in order to achieve comparable cellular doxorubicin levels prior to retention experiments. The 3 h uptake followed by retention was carried out in order to mimic the protocol used for cytotoxicity experiments. In L1210/S cells treated with the IC50 of DOX in the absence or presence of 5 gM TFP, DOX retention was 50-70% of that initially accumulated and represented approximately 5 ng DOX 10-6 cells. In contrast, while DOX The effect of TFP on DOX and VP-16 induced DNA-SSB in L1210/S and L1210/DT cells is shown in Figure 4 . Induction of DNA-single strand breaks by equimolar doses of DOX and VP-16 were 2-4-fold lower in L1210/DT vs L1210/S cells. However, in both L1210/S and L1210/DT cells, DNA strand breaks induced by DOX or VP-16 were potentiated in the presence of 5 gM TFP.
The levels of the TOPO II using antisera specific for 170 kDa and 180 kDa isoforms of TOPO II are shown in Figure 5 . The results show that the levels of the two isoforms of TOPO II (170 kDa and 180 kDa) in the L1210/S and L1210/DT cells are comparable.
The amount of P-glycoprotein in L1210/S and L1210/DT cells following metabolic labelling with [32P]orthophosphoric acid is shown in Figure 6 . Results demonstrate the absence of any phosphorylated PGP in L1210/S cells which is consistent with the lack of overexpression of PGP in these cells (Ganapathi et al., 1991a) . However, in the L1210/DT cells, the overexpression and phosphorylation of PGP is readily apparent.
Discussion
Drug resistance in the chemotherapy of cancer continues to be a constant challenge. Although mechanisms of resistance could be specific for a given class of agents, expression of resistance to drugs with different mechanistic basis for cytotoxicity has been a subject of considerable interest (Endicott & Ling, 1989 (Endicott & Ling, 1989; Ford & Hait, 1990 ).
Since the occurrence of resistant tumour cells is not uncommon, the use of the modulating agents in combination treament has been suggested to prevent emergence of multidrug resistant cells (salmon, et al., 1991) . Among the modulation agents, verapamil has been the most widely studied (Endicott & Ling, 1989; Ford & Hait, 1990) . Our previous studies have focussed on trifluoperazine as a modulating agent and while its efficacy in affecting vinca alkaloid cytotoxicity was dependent on enhancing cellular drug levels, the potentiation of cytotoxicity with inhibitors of TOPO II was not correlative with corresponding increases in drug accumulation (Ganapathi et al., 1991b) .
In this report, we demonstrate that the inclusion of TFP with minimally cytotoxic concentrations of DOX can induce the selection of cells with the MDR phenotype. While the L1210/DT cells were selected following exposure of L1210/S cells to 0.017 7 M DOX + 5 LM TFP, to achieve comparable levels of resistance, Li210/S cells in previous experiments had to be progessively exposed with up to 20-fold higher concentrations of DOX (Ganapathi & Grabowski, 1988) .
The results in Figure 1 demonstrate that the L1210/DT cells are cross resistant to inhibitors of TOPO II and vincristine. No cross-resistance to the topoisomerase I inhibitor camptothecin, was observed (data not shown). The expression of resistance to VCR in L1210/DT cells was not surprising based on the overexpression of PGP and this is consistent with the relationship between overexpression of PGP and VCR resistance (Ganapathi et al., 1991b suggests a role for PGP overexpression. However, the data in Figure 3 simulating treatment conditions for cell survival data in Figure 1 suggest the following: (a) At the IC50 of DOX alone, DOX retention at near steady state is 5-fold higher in the L1210/DT vs L1210/S cells; (b) In L1210/DT cells treated with the IC50 of DOX ± 5 gM TFP, the percent of DOX retained is comparable; and (c) cellular DOX levels for equivalent kill in L1210/DT cells were>2-fold higher in absence vs presence of TFP. The requirement of higher DOX levels for equivalent cell kill is also apparent in the data on induction of DNA-SSB by DOX and VP-16 (Figure 4) . The reduced induction of DNA-SSB is not correlative with corresponding changes in drug levels and may be related to selective alterations in drug stimulated DNA cleavage activity without reduction in levels ( Figure 5) (Bellamy et al., 1990; Chen et al., 1990) . The absence of DOX resistance in cells adapted to grow in TFP alone is comparable to that reported with verapamil alone (Twentyman et al., 1990) based on pharmacological effects may not affect putative targets of DOX cytotoxicity when used alone. Further, the continued ability of TFP to modulate DOX resistance in L1210/DT cells, while surprising, suggest that targets involved in modulation are possibly not compromised.
In summary, results from this study demonstrate that noncytotoxic concentrations of 5fLM TFP in combination with 0.017 fLM DOX can induce selection of > 30-fold DOXresistant cells with the MDR phenotype. The mechanisms of resistance which involve alterations in TOPO II mediated DNA strand breaks and PGP overexpression in cells selected with DOX + TFP are comparable to that observed in cells following selection with DOX alone. Although a potentiation in the development of resistance clinically needs to be carefully assessed, a combination of DOX plus verapamil in tumour bearing mice has also been suggested to lead to the rapid development of resistance (Formelli et al., 1988) . 
